Table 3.
Univariate Cox Regression Analysis of OS and PFS
| Characteristics | OS | PFS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age (years) | 0.096 | 0.481 | ||||
| <60 | 1.000 | 1.0000 | ||||
| ≥60 | 0.747 | 0.530–1.053 | 0.875 | 0.605–1.267 | ||
| Gender | 0.809 | 0.994 | ||||
| Male | 1.000 | 0.744–1.462 | 1.000 | 0.692–1.441 | ||
| Female | 1.043 | 0.998 | ||||
| Smoke | 0.099 | 0.071 | ||||
| No | 1.000 | 0.535–1.055 | 1.000 | 0.497–1.029 | ||
| Yes | 0.751 | 0.715 | ||||
| KPS | 0.001 | 0.005 | ||||
| 90–100 | 1.000 | 1.245–2.512 | 1.000 | 1.184–2.530 | ||
| 70-80 | 1.768 | 1.731 | ||||
| Patient histology | 0.894 | 0.553 | ||||
| SCC | 1.000 | 0.730–1.433 | 1.000 | 0.774–1.613 | ||
| AD | 1.023 | 1.117 | ||||
| Differentiation | 0.002 | 0.003 | ||||
| Well/Moderate | 1.000 | 1.252–2.647 | 1.000 | 1.235–2.784 | ||
| Poor | 1.820 | 1.854 | ||||
| Tumor site | 0.111 | 0.248 | ||||
| Left | 1.000 | 0.939–1.848 | 1.000 | 0.861–1.785 | ||
| Right | 1.317 | 1.240 | ||||
| Primary tumor size | 0.012 | 0.179 | ||||
| ≤ 4 cm | 1.000 | 1.102–2.183 | 1.000 | 0.893–1.841 | ||
| > 4 cm | 1.551 | 1.282 | ||||
| cTNM status | 0.001 | 0.004 | ||||
| IIIA | 1.000 | 1.291–2.654 | 1.000 | 1.209–2.640 | ||
| IIIB | 1.851 | 1.786 | ||||
| Serum CEA(ng/mL) | 0.660 | 0.979 | ||||
| Normal | 1.000 | 0.765–1.526 | 1.000 | 0.691–1.462 | ||
| High | 1.081 | 1.005 | ||||
| CYFRA21-1(ng/mL) | 0.20 | 0.08 | ||||
| Normal | 1.000 | 0.560–1.129 | 0 | 1.000 | 0.493–1.042 | 1 |
| High | 0.795 | 0.717 | ||||
| Treatment modality | 0.11 | 0.13 | ||||
| CCRT | 1.000 | 0.933–1.843 | 8 | 1.000 | 0.914–1.909 | 8 |
| SCRT | 1.311 | 1.321 | ||||
| Response rate | 0.022 | 0.006 | ||||
| CR+PR | 1.000 | 1.064–2.190 | 1.000 | 1.174–2.607 | ||
| SD+PD | 1.526 | 1.749 | ||||
| NPS Group | <0.001 | <0.001 | ||||
| 0,1 | 1.000 | 1.845– | 1.000 | 1.600– | ||
| 2 | 2.691 | 3.925 | 2.356 | 3.468 | ||
Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; KPS, Karnofsky performance score; SCC, squamous cell carcinoma; AD, adenocarcinoma; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 19 fragments; CCRT, concurrent chemoradiotherapy; SCRT, sequential chemoradiotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.